Drilldown: Medicines

Other values:

Search

None (69) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1) · ReVia (oral, 50 mg tablets), Depade (oral, generic), Vivitrol (extended-release IM injection 380 mg monthly); Contrave (naltrexone + bupropion ER tablets for weight management) (1)

Research material · Classic Psychedelic · Stimulant · Opioid · Sedative-Hypnotic · Phenethylamine · Tryptamine · Benzodiazepine · Botanical · [[:Category:Antihypertensives|Antihypertensive]] · Dissociative · Anticonvulsant · Antidepressant · Plant Medicine · Analgesic · Antiparkinsonian · Antipsychotic · Empathogen · Neuroleptic · Cathinone

Other values:

Search

None (1) · 1-acetyl-LSD; prodrug of LSD (1) · 5-HT2A agonist (26) · 5-HT2A agonist; D2 partial agonist (1) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A agonist; minor psilocybin mushroom alkaloid (1) · 5-HT2A agonist; primarily auditory effects (1) · 5-HT2A agonist; sigma-1 agonist (1) · 5-HT2A partial agonist (2) · Contains bufotenin and DMT (1) · Contains LSA (2) · Contains mescaline (2) · Contains psilocybin and psilocin (1) · DMT + MAOI (harmine/harmaline); 5-HT2A agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · LSD analogue; 5-HT2A agonist (4) · Lysergic acid 2,4-dimethylazetidide; 5-HT2A agonist (1) · Lysergic acid hydroxyethylamide; 5-HT2A agonist (1) · Monoamine releasing agent; 5-HT2A agonist (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; sigma-1 agonist (1) · Potent 5-HT2A agonist; very long duration (1) · Prodrug of 4-HO-DET; 5-HT2A agonist (1) · Prodrug of 4-HO-DiPT; 5-HT2A agonist (1) · Prodrug of 4-HO-MET; 5-HT2A agonist (1) · Prodrug of 4-HO-MiPT; 5-HT2A agonist (1) · Prodrug of LSD; 5-HT2A agonist (4) · Prodrug of psilocin; 5-HT2A agonist (1) · Serotonin/dopamine/norepinephrine releasing agent; 5-HT2A agonist (1) · Very potent 5-HT2A agonist; long duration (1)

None (72)

None (72)

None (71) · Oral tablets 50 mg (ReVia, Depade, generics); Vivitrol extended-release IM suspension 380 mg single-dose vial; Contrave (naltrexone 8 mg + bupropion 90 mg ER tablets); compounded 1, 2, 3, 4.5 mg tablets/capsules for LDN (1)

None (71) · 50 mg/day oral; 380 mg/4 weeks IM (Vivitrol); 32 mg + 360 mg naltrexone/bupropion daily (Contrave maximum after titration) (1)

None (69) · insufflated (1) · intramuscular (depot) (1) · Oral (3) · PR (1)

None (69) · 30–60 minutes (1) · 45-75 min (oral) (1) · Oral peak plasma 1 hour; therapeutic opioid blockade within hours of first dose. IM Vivitrol: peak plasma 2-3 days; therapeutic blockade through the dosing interval. (1)

None (69) · 4-8 h (1) · 8–12 hours (1) · Oral mu-blockade clinically meaningful for 24-72 hours; IM Vivitrol blockade through 4 weeks. (1)

None (69) · 3–5 hours (1) · Naltrexone parent ~4 hours (oral); 6-beta-naltrexol (active metabolite) ~13 hours. Vivitrol depot terminal half-life 5-10 days with sustained release from microspheres maintaining blockade for the 4-week dosing interval.'"`UNIQ--ref-0000004F-QINU`"' (1) · Not well characterized (1)

None (69) · 70–90% (oral) (1) · Not well characterized (1) · ~5-40% (oral, highly variable due to extensive first-pass metabolism; mean ~5-10% for parent naltrexone with the majority of pharmacologic effect coming from 6-beta-naltrexol). IM Vivitrol bypasses first-pass entirely.'"`UNIQ--ref-00000050-QINU`"' (1)

None (70) · Not established (2)

None (70) · Schedule I (United States) (1) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1)